SMAD3 and diabetic kidney disease: In contrast, an inhibitory Smad, Smad7, represses TGF-β/Smad3 and NF-κB signaling pathway by interacting with TGF-β receptors and functions as an antagonist of these molecules in diabetic nephropathy [10].